Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
-
Entrada Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).
-
Entrada Therapeutics reports financial results for the fourth quarter and full year ended December 31, 2025, and highlights recent business updates.
-
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
-
Entrada Therapeutics announces that the Company will participate in two upcoming investor conferences.
-
Entrada Therapeutics reports progress across its portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.
-
Entrada Therapeutics announces an upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference.
-
Entrada Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).
-
Entrada Therapeutics reports financial results for the third quarter ended September 30, 2025, and highlights recent business updates.
-
Entrada Therapeutics announces that the Company will participate in two upcoming investor conferences.